Skip to Content
Merck
CN
All Photos(1)

Key Documents

1224981

USP

Donepezil hydrochloride

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

(±)-2-[(1-Benzyl-4-piperidyl)methyl]-5,6-dimethoxy-1-indanone hydrochloride, 2,3-Dihydro-5,6-dimethoxy-2-{[1-(phenylmethyl)-4-piperidinyl]methyl}-1H-inden-1-one

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C24H29NO3 · HCl
CAS Number:
120011-70-3
Molecular Weight:
415.95
MDL number:
MFCD00881312
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

donepezil

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

Cl.N2(CCC(CC2)CC3Cc4c(cc(c(c4)OC)OC)C3=O)Cc1ccccc1

InChI

1S/C24H29NO3.ClH/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18;/h3-7,14-15,17,20H,8-13,16H2,1-2H3;1H

InChI key

XWAIAVWHZJNZQQ-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

1224992

Donepezil related compound A, United States Pharmacopeia (USP) Reference Standard

1171819

Desbenzyl donepezil hydrochloride, United States Pharmacopeia (USP) Reference Standard

1224970

Donepezil-N-oxide, United States Pharmacopeia (USP) Reference Standard

PHR2023

(E)-2-[(1-Benzylpiperidin-4-yl)methylene]-5,6-dimethoxyindan-1-one(Donepezil Related Compound A), Pharmaceutical Secondary Standard; Certified Reference Material

PHR2024

Donepezil-N-Oxide, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2025

Desbenzyl donepezil hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

Y0002165

Donepezil for system suitability, CRS, European Pharmacopoeia (EP) Reference Standard

Y0002160

Donepezil hydrochloride, CRS, European Pharmacopoeia (EP) Reference Standard

Pictograms

Skull and crossbones
GHS06

Signal Word

Danger

Hazard Statements

H300,H319

Hazard Classifications

Acute Tox. 2 Oral - Eye Irrit. 2

Storage Class Code

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

H Sugimoto et al.
Current medicinal chemistry, 7(3), 303-339 (2000-01-19)
A wide range of evidence shows that acetylcholinesterase (AChE) inhibitors can interfere with the progression of Alzheimer's disease (AD). The successful development of these compounds was based on a well-accepted theory that the decline in cognitive and mental functions associated
Warren B Zigman
Developmental disabilities research reviews, 18(1), 51-67 (2013-08-21)
At present, there may be over 210,000 people with Down syndrome (DS) over the age of 55 in the United States (US) who have significant needs for augmented services due to circumstances related to ordinary and/or pathological aging. From 1979
Koteswara Rao Valasani et al.
Journal of chemical information and modeling, 53(8), 2033-2046 (2013-06-20)
Acetylcholinesterase (AChE) is a main drug target, and its inhibitors have demonstrated functionality in the symptomatic treatment of Alzheimer's disease (AD). In this study, a series of novel AChE inhibitors were designed and their inhibitory activity was evaluated with 2D
Kenneth Rockwood et al.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 40(4), 564-571 (2013-06-22)
vascular dementia (VaD) and mixed Alzheimer's disease (AD/VaD) are common. How best to monitor treatment is not clear. Our objective was to compare responsiveness and construct validity of change scores, following donepezil treatment, of the standardized Mini-Mental State Examination (sMMSE)
Hachiro Sugimoto et al.
Japanese journal of pharmacology, 89(1), 7-20 (2002-06-27)
A wide range of evidence shows that cholinesterase (ChE) inhibitors can interfere with the progression of Alzheimer's disease (AD). The earliest known ChE inhibitors, namely, physostigmine and tacrine, showed modest improvement in the cognitive function of AD patients. However, clinical
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service